1. HBW Insight
  2. >>Supply Chain

US Infant Formula Safety Questions Don’t Include Cronobacter National Reportable Disease Listing

 
• By Malcolm Spicer

FDA submitted four questions for USDA committee's advice on strengthening prevention of cronobactera contaminations such as problem leading to Abbott facility shutdown earlier in 2022 and supply shortage still affecting US. "High mortality rate of infants infected with cronobacter sakazakii should be enough for consumers expect this issue to receive an urgent response,” Stop Foodborne Illness CEO Mitzi Baum tells FDA and USDA.

• Source: Shutterstock

Numerous questions remain unanswered about preventing further problems with cronobacter bacteria contamination in infant formula marketed in the US, but one answer the Food and Drug Administration and food safety advocates suggest is requiring national disease reporting for cronobacter.

The FDA has submitted four questions (see below) to the Department of Agriculture's National Advisory Committee on Microbiological Criteria for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Supply Chain

US Consumer Health, Beauty Sectors: Expecting Tariff Policy Changes, Buckling Up For The Ride

 
• By Malcolm Spicer

As firms in OTC drug, dietary supplement and personal care/beauty sectors reported results for January-March period after Trump announced reciprocal tariffs, they buckled up for more changes in the president’s thinking likely to affect consumer spending as well as their costs.

OTC Drug, Supplement Trade Groups Argue For Tariff Exemption, International Supply Chain

 
• By Malcolm Spicer

Potential for supply disruption coupled with manufacturers’ costs for moving supply chains to US emphasized by industry trade groups in comments submitted to Department of Commerce on whether pharmaceutical and dietary ingredients should remain exempted from tariffs President Trump has imposed.

Rapidly Changing Market Demands Quick Study From Consumer Health, Personal Care Marketers

 
• By Malcolm Spicer

“It is shifting so quickly. It's shifting underneath our feet,” says NielsenIQ wellness VP Sherry Frey. Even comparing the past year to the preceding eight, “it's just accelerating quicker and quicker, and one of the biggest areas is online.”

China Distribution Disruption Drags Kenvue Results

 
• By Malcolm Spicer

CEO Thibaut Mongon says Kenvue’s results for current quarter will be affected by “lingering impact of the distribution disruption we saw in China,” which “will take a little bit of time to fix.” Also, activist investor Starboard wants to bring “significant changes” to the board at firm’s annual shareholder meeting later in year.

More from HBW Insight

FDA’s FY 2026 Budget Request Lacks New Policy Proposals

 
• By Sue Sutter

The White House requested $6.8bn for the FDA, down 3.9% from the current funding level, but does not propose any legislative changes. In previous years, the agency used the budget process to seek statutory fixes specific to generic drugs and shortages.

House Appropriators’ $3.2Bn For FDA In FY 2026 Includes More Non-User Fee Funds Than Requested

 
• By Sue Sutter and Derrick Gingery

A US House bill would give the FDA $33.1m more in budget authority than requested by the Trump Administration for fiscal year 2026. The measure was sent to the full House Appropriations committee on a party-line vote.

EU Pharma Reform: Council Proposes Rx Exemption For Topical Antimicrobials

 
• By David Ridley

The EU Council has introduced a key amendment to Article 51 (para 1, point e) of the new pharma directive: “A medicinal product shall be subject to medical prescription where it is an antimicrobial, unless intended for topical use.”